The current and future disease burden of chronic hepatitis C virus infection in Egypt

SummaryBackgroundThe prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.AimA modelling approach was used to quantify the current HCV‐infected population, future disease progression and associated costs in Egypt.MethodsDirect healthcare costs were calculated from a nationally representative hospital and a disability adjusted life year (DALY) template was used with monetary value assigned to lost life years. Three scenarios were considered: (i) Historical treatment scenario: 50% SVR; 65 000 treated annually, (ii) Current treatment scenario: 90% sustained virologic response (SVR); 65 000 treated annually, (iii) Increased treatment scenario: 90% SVR; 325 000 treated annually by 2018.ResultsCumulative DALYs (2015–2030) under Scenario 1 were estimated at 7.88 million and cumulative costs estimated at $89.07 billion. Annual DALYs increased 16% during 2015–2030 while annual costs more than doubled. Scenario 2 reduced cumulative DALYs and costs by 7% and 4%, respectively. Under Scenario 3, total costs declined 73% to $1047 million during 2015–2030. As compared to Scenario 1, cumulative DALYs and costs decreased 37% and 35%, respectively.ConclusionsThis is the first estimate of the total economic burden of HCV in Egypt. Extraordinary measures are necessary to substantially reduce HCV disease and cost burden. With newer therapies, strategies to reduce disease burden are feasible and cost‐effective.

show abstract

“…Previous analysis estimated approximately 65 000 HCV patients were treated with pegylated interferon in 2014 6, 19…”

Section: Methodsmentioning

confidence: 99%

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Estes

Abdel-Kareem²,

Abdel-Razek³

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Hepatitis imposes a heavy burden, both in terms of clinical management and epidemiology in the Arab world, especially Egypt [3]. Chronic hepatitis patients showed non-significant changes in liver function tests.…”

Section: Hepatitismentioning

confidence: 99%

Ramadan fasting and infectious diseases: a systematic review

Bragazzi

Briki

Khabbache

et al. 2015

J Infect Dev Ctries

View full text Add to dashboard Cite

Ramadan represents the fourth of the five pillars of the Islamic creed. Although patients are exempted from observing this duty, they may be eager to share this moment of the year with their peers. However, there are no guidelines that can help physicians to address the concerns of patients with infectious diseases fasting during Ramadan. For this purpose, we performed a systematic review. of 51 articles. Our main findings are that: 1) patients suffering from diabetes at risk of developing infectious complications should not fast; 2) Ramadan fasting has little impact on diarrheal patients; 3) HIV represents a challenge, and ad hoc drug combinations should be recommended to patients, and the patients should be advised not to take fatty meals that could interfere with the treatment; 4) Ramadan has no effect on the effectiveness of anti-helminthic therapy; and 5) patients with active ulcers should not fast, as they have a higher probability of developing complications.

show abstract

“…Egypt has the highest prevalence of HCV which was estimated to be 7.3% with predominance of genotype 4 [1]. Acute HCV infection usually lead to no symptoms and about 75 % of cases infected with HCV reach a chronic stage leading to chronic HCV infection [2].…”

Section: Introductionmentioning

confidence: 99%

Fibrosis Regression after Treatment with Daas

Mehrez¹

2017

GHOA

View full text Add to dashboard Cite

Background: HCV infection promote liver fibrogenesis by direct and indirect mechanisms through chronic inflammation. Successful HCV treatment was associated with significant improvement in liver histology. Non-invasive methods (like APRI score and Fib-4 index) for the evaluation of liver fibrosis have been developed and validated.Methods: Fib-4 index and APRI score were calculated for 50 Egyptian chronic HCV (genotype 4) patients who received sofosbuvir (400 mg once daily) plus simeprevir (150 mg once daily) for 12 weeks. The end-point was a sustained virological response at 12 (SVR12) weeks post treatment.Results: Baseline fibrosis stage showed a mean APRI score of 0.63188 and mean Fib-4 index of 1.97210. All patients had an end of treatment response with negative HCV RNA. Improvement in liver enzymes and platelet count was reflected on the regression of fibrosis after treatment with a significant reduction in levels of both APRI score and Fib-4 index. Conclusion:Fibrosis regression -assessed by non-invasive markers of fibrosisis achievable upon removal of the causative agent.

show abstract

The current and future disease burden of chronic hepatitis C virus infection in Egypt

Cited by 104 publications

References 61 publications

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Ramadan fasting and infectious diseases: a systematic review

Fibrosis Regression after Treatment with Daas

Contact Info

Product

Resources

About